Ophthalmic laser manufacturer Norlase has announced the immediate commercial launch and FDA 510(k) clearance and CE Mark for LYNX, the company’s pattern scanning laser indirect ophthalmoscope (LIO). In a company press release, Norlase said it is the first and only LIO with integrated pattern-scanning capabilities. LYNX is battery-powered and thus provides surgeons with an “untethered” laser solution that enables them to treat virtually anywhere. The laser and pattern module is built into the ergonomic headset, eliminating the need for an external laser source. Surgeons can now move freely and efficiently during treatment with advanced features such as an intuitive wireless user interface offering surgeons more options to streamline their treatment flow, Norlase said.

Other notable LYNX features include:

• Full pattern palette includes 2x2 to 5x5 grids, triple arcs and circles
• simplyCLEAR safety filters for enhanced visualization 
• Multilingual voice control of patterns and parameters.

"The most important resource for today's ophthalmologists is time," said Oliver Hvidt, CEO and co-founder of Norlase, in the press release. "That's why they've been asking for pattern LIO ever since the invention of pattern lasers more than 15 years ago. With LYNX, pattern LIO is finally here. Faster LIO treatments means less ergonomic stress, more quality time with patients and more practice days that end on time.”